“…Notably, ELFs are described at all stages of the disease and include patients with early active disease who have not received biological agents, patents with more progressive forms of rheumatoid arthritis, and those that have already received biological intervention 43, 112, 113. Although the mechanisms contributing the development of this form of pathology are largely unclear, ELFs in rheumatoid arthritis are associated with heightened synovial expression of CXCL13, CCL21, CCL19 and CXCL12, and cytokines LT α
1
β
2 and IL‐7 21, 44, 114, 115. Importantly, these structures correlate with disease severity and are associated with local T‐cell priming and autoantibody production 43, 116, 117, 118.…”